Therapeutic effectiveness of a generic versus original meropenem in serious infections

Journal of the Medical Association of Thailand

Volumn 94, Issue 2, 2011, Pages 172-178

  Tansuphasawadikul, Somboon ^a   Simaroj, Songchai ^b   Chantarothorn, Somchai ^c   Nuntachit, Nontakan ^d   Jutivorakool, Kamonwan ^e   Munsakul, Warangkana ^f   Yomtem, Kanittha ^g   Tangkosakul, Thitirat ^h   Wannasunthornchai, Suppaleark ⁱ  

^a Buddhachinnaraj Hospital   (Thailand)

^b POLICE GENERAL HOSPITAL   (Thailand)

^c Somdej Phrapinklao Hospital   (Thailand)

^d CHIANG MAI UNIVERSITY   (Thailand)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^g Narathiwas Hospital   (Thailand)

^h LERDSIN GENERAL HOSPITAL   (Thailand)

ⁱ Udonthani Hospital   (Thailand)

Author keywords

Carbapenems; Effectiveness; Generic; Meropenem; Original

Indexed keywords

CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; GENERIC DRUG; MAPENEM; MEROPENEM; METRONIDAZOLE; SULPERAZON; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; AGE; AGED; ARTICLE; BACTERIAL INFECTION; BLOODSTREAM INFECTION; BODY WEIGHT; BONE INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INFECTIOUS ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PANCYTOPENIA; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SEIZURE; SEX DIFFERENCE; SKIN INFECTION; SOFT TISSUE INFECTION; TERTIARY HEALTH CARE; THAILAND; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COHORT STUDIES; DRUGS, GENERIC; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INPATIENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THAILAND; THIENAMYCINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952322164     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kallen AJ, Hidron AI, Patel J, Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 2010; 31: 528-531.
2. Werarak P, Kiratisin P, Thamlikitkul V. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance. J Med Assoc Thai 2010; 93 (Suppl 1): S126-S138.
3. Sirichot S, Diraphat P, Utrarachkij F, Tribuddharat C, Siripanichgon K. Dissemination of class I integron in Acinetobacter baumliannii isolated from ventilator-associated pneumonia patients and their environment. Southeast Asian J Trop Med Public Health 2009; 40: 1284-1292.
4. Mohr JF III. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 2008; 47 (Suppl 1): S41-S51.
5. Baughman RP. The use of carbapenems in the treatment of serious infections. J Intensive Care Med 2009; 24: 230-241.
6. Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008; 68: 803-838.
7. Silva E, Diaz JA, Arias MJ, Hernandez AP, de la Torre A. Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products for intravenous administration. BMC Clin Pharmacol 2010; 10: 3.
8. Leelarasamee A, Rongrungruang Y, Trakulsomboon S, Pongpech P, Thanawattanawanich P, Jithavech P. Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem). J Med Assoc Thai 2008; 91: 980-988.
9. Berman SJ, Fogarty CM, Fabian T, Melnick D, Lesky W. Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. J Chemother 2004; 16: 362-371.
10. Alvarez Lerma F. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13: 70-81.
11. Bartoloni A, Strohmeyer M, Corti G, Buonomini MI, Franchino L, Romanelli G, et al. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs Exp Clin Res 1999; 25: 243-252.
12. Punpanich W, Tantichattanon W, Wong-watcharapaiboon S, Treeratweeraphong V. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. J Med Assoc Thai 2008; 91 (Suppl 3): S21-S27.
13. Thapa B, Tribuddharat C, Srifuengfung S, Dhiraputra C. High prevalence of bla(OXA)-23 in oligoclonal carbapenem-resistant Acinetobacter baumannii from Siriraj Hospital, Mahidol University, Bangkok, Thailand. Southeast Asian J Trop Med Public Health 2010; 41: 625-635.
14. Pongpech P, Amornnopparattanakul S, Panapakdee S, Fungwithaya S, Nannha P, Dhiraputra C, et al. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii. J Med Assoc Thai 2010; 93: 161-171.
15. Kiratisin P, Apisarnthanarak A, Kaewdaeng S. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int J Antimicrob Agents 2010; 36: 243-246.
16. Rongrungruang Y, Rittayamai N, Sangswangchot P, Koomanachai P, Rattanaumpawan P, Chinswangwatanakul V, et al. A prospective open-label study on effectiveness and safety of a generic meropenem. J Infect Dis Antimicrob Agents 2010; 27: 11-22.